CAPTRUST Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.53M | Buy |
12,176
+4,866
| +67% | +$612K | ﹤0.01% | 1107 |
|
|
2025
Q1 | $808K | Sell |
7,310
-4,334
| -37% | -$479K | ﹤0.01% | 1387 |
|
|
2024
Q4 | $1.59M | Buy |
11,644
+1,836
| +19% | +$251K | ﹤0.01% | 984 |
|
|
2024
Q3 | $1.13M | Buy |
9,808
+52
| +0.5% | +$5.99K | ﹤0.01% | 1122 |
|
|
2024
Q2 | $1.34M | Buy |
9,756
+1,598
| +20% | +$220K | ﹤0.01% | 987 |
|
|
2024
Q1 | $1.13M | Sell |
8,158
-3,673
| -31% | -$507K | ﹤0.01% | 1065 |
|
|
2023
Q4 | $1.56M | Buy |
11,831
+8,355
| +240% | +$1.1M | 0.01% | 1027 |
|
|
2023
Q3 | $391K | Buy |
3,476
+493
| +17% | +$55.5K | ﹤0.01% | 1813 |
|
|
2023
Q2 | $281K | Buy |
2,983
+100
| +3% | +$9.43K | ﹤0.01% | 2024 |
|
|
2023
Q1 | $292K | Sell |
2,883
-63
| -2% | -$6.38K | ﹤0.01% | 1765 |
|
|
2022
Q4 | $352K | Buy |
2,946
+1,017
| +53% | +$121K | ﹤0.01% | 1542 |
|
|
2022
Q3 | $205K | Buy |
1,929
+265
| +16% | +$28.2K | ﹤0.01% | 1810 |
|
|
2022
Q2 | $162K | Buy |
1,664
+270
| +19% | +$26.3K | ﹤0.01% | 1848 |
|
|
2022
Q1 | $131K | Sell |
1,394
-105
| -7% | -$9.87K | ﹤0.01% | 2064 |
|
|
2021
Q4 | $128K | Buy |
1,499
+232
| +18% | +$19.8K | ﹤0.01% | 1961 |
|
|
2021
Q3 | $122K | Buy |
1,267
+31
| +3% | +$2.99K | ﹤0.01% | 1915 |
|
|
2021
Q2 | $120K | Buy |
1,236
+205
| +20% | +$19.9K | ﹤0.01% | 1880 |
|
|
2021
Q1 | $100K | Buy |
+1,031
| New | +$100K | ﹤0.01% | 1952 |
|
|
2019
Q4 | – | Sell |
-107
| Closed | -$10K | – | 1504 |
|
|
2019
Q3 | $10K | Hold |
107
| – | – | ﹤0.01% | 1502 |
|
|
2019
Q2 | $9K | Hold |
107
| – | – | ﹤0.01% | 1531 |
|
|
2019
Q1 | $9K | Buy |
+107
| New | +$9K | ﹤0.01% | 1415 |
|
|
2018
Q4 | – | Sell |
-154
| Closed | -$19K | – | 1641 |
|
|
2018
Q3 | $19K | Buy |
+154
| New | +$19K | ﹤0.01% | 1026 |
|